Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "SUIT-003 O2 ce D061"

From Bioblast
Β 
(17 intermediate revisions by 5 users not shown)
Line 1: Line 1:
{{MitoPedia
{{MitoPedia
|abbr=ce
|abbr=CCP-ce Snv,Mnanv - control
|description=[[File:Ce1;ce2Omy;ce3U;ce4Rot;ce5S;ce6Mnanv;ce7Ama.png|400px]]
|description=[[File:ce1;(ce2Omy);ce3U;ce4Rot;ce5DMSO;ce6DMSO;ce7Ama.png|400px]]
|info='''B''' -Β  complex cell [[coupling control protocol]] (CCP) with the Prodrug of malonate [[NV161/MitoKit-CII|NV161]]-'''[[SUIT-003]]'''
|info='''B''' Carrier control for the [[coupling-control protocol]] for [[living cells]] with cell permeable compounds [[MitoKit-CII/Succinate-nv]] and [[MitoKit-CII/Malonate-nv]] - [[SUIT-003 O2 ce D060]]
|application=O2
|SUIT number=D061_ce1;(ce2Omy);ce3U;ce4Rot;ce5DMSO;ce6DMSO;ce7Ama
}}
}}
::: '''[[SUIT protocol pattern]]:''' ce1;ce2Omy;ce3U;ce4Rot;ce5S;ce6Mnanv;ce7Ama
::: '''[[MitoPedia: SUIT]]''' - Coupling-control protocol (CCP) with the carrier of the plasma membrane-permeable succinate ([[MitoKit-CII/Succinate-nv]]) and plasma membrane-permeable malonate ([[MitoKit-CII/Malonate-nv]]) in living cells (ce): DMSO.
::: '''[[SUIT protocol pattern]]:''' ce1;(ce2Omy);ce3U;ce4DMSO;ce5DMSO;ce6Rot;ce7Ama


SUIT-003 O2 ce-pce D061 is designed to study [[coupling control state| coupling control]] and the presence of succinate transporters in the plasma membrane of living cells. Respiratory capacities are tested in a sequence of coupling states: [[ROUTINE]], [[LEAK]] and [[ET]]. To study [[LEAK-respiration]], the [[phosphorylation system]] is inhibited by [[oligomycin]]. The final concentration of [[oligomycin]] has to be carefully optimized for various cell types, to minimize the inhibitory effect on the [[Electron transfer-pathway|electron transfer system]] which would lead to an underestimation of [[ET-capacity]]. The addition of succinate after rotenone will allow us to stimulate the respiration in living cells expressing a succinate transporter in the plasma membrane and those cells that present a damage plasma membrane and are permeable to the substrate. However, the use of the [[NV161/MitoKit-CII| Prodrug of malonate (Mnanv)]] allows us to differentiate between these two possible sources of stimulation in the respiration. The permeable compounds only work in living cells which a non-altered plasma membrane due that to be active the cytosolic esterases must cleavage the compound. The living cells with an altered permeability of the plasma membrane will not be affected by the used of the [[NV161/MitoKit-CII| Prodrug of malonate (Mnanv)]].
{{Template:SUIT text D061}}
SUIT-003 O2 ce D061 protocol is a control for the [[SUIT-003 O2 ce D060]], with the addition of the [[Carrier control titrations|carrier]] DMSO instead of the plasma membrane-permeable succinate ([[[MitoKit-CII/Succinate-nv]]) and plasma membrane-permeable malonate ([[MitoKit-CII/Malonate-nv]]). Moreover, the SUIT-003 O2 ce D061 protocol allows evaluating the [[coupling control state |coupling control]] of living cells. Respiratory capacities are tested in a sequence of coupling states: [[ROUTINE]] and [[Electron transfer pathway]]. Optionally, to study [[LEAK respiration]], the [[phosphorylation system]] might be inhibited by [[oligomycin]]. The final concentration of [[oligomycin]] has to be carefully optimized for various cell types, to minimize the inhibitory effect on the [[Electron transfer pathway|electron transfer system]] which would lead to an underestimation of [[ET capacity]]. Β 




__TOC__
__TOC__
Β  Communicated byΒ  [[Garcia-Souza LF]] and [[Gnaiger E]](last update 2019-06-24)
Β  Communicated byΒ  [[Garcia-Souza LF]], [[Cardoso LHD]] and [[Gnaiger E]](last update 2019-07-02)


{{Template:SUIT-003 O2 ce D061}}
{{Template:SUIT-003 O2 ce D061}}


== Strengths and limitations ==
== Strengths and limitations ==
:::* The [[SUIT-003 O2 ce D061]] is a cell [[coupling control protocol]]. The total cell count (''N''<sub>ce</sub>) is the sum of viable cells (''N''<sub>vce</sub>) and dead cells (''N''<sub>dce</sub>).
:::+ This protocol is a control for [[SUIT-003 O2 ce D060]], with titrations of the carrier DMSO.
:::* [[CIV]] activity can also be measured after the cell viability test module.
:::+ Reasonable duration of the experiment.
:::- The addition of [[oligomycin]] has to be carefully tested to avoid inhibitory effects in the evaluation of the [[ET-capacity]].
:::- To obtain [[LEAK respiration]], the concentration of [[oligomycin]] has to be carefully tested to avoid inhibitory effects in the evaluation of the [[ET capacity]].
:::- Careful washing is required after the experiment to avoid carry-over of inhibitors and uncoupler.
:::- Careful washing is required after the experiment to avoid carry-over of inhibitors and uncoupler.




== Compare SUIT protocols ==
== Compare SUIT protocols ==
::::* [[SUIT-003 O2 ce D060]] CCP with cell permeable compounds [[NV118/MitoKit-CII|NV118]] and [[NV161/MitoKit-CII|NV161]]
::::* [[SUIT-003 O2 ce D060]] CCP with plasma membrane-permeable compounds [[MitoKit-CII/Succinate-nv]] and [[MitoKit-CII/Malonate-nv]].
::::* [[SUIT-003 O2 ce D028]] for cell membrane permeability test CCP(S).
::::* [[SUIT-003 O2 ce D028]] for cell membrane permeability test CCP(S).
::::* [[SUIT-003 O2 ce-pce D013]] first version of the Coupling control protocol and respirometric cell viability test (CCV protocol).
::::* [[SUIT-003 O2 ce-pce D013]] first version of the Coupling-control protocol and respirometric cell viability test (CCV protocol).
::::* [[SUIT-003 O2 ce-pce D018]] second version of the Coupling control protocol and respirometric cell viability test (CCV protocol).
::::* [[SUIT-003 O2 ce-pce D018]] second version of the Coupling-control protocol and respirometric cell viability test (CCV protocol).
::::* [[SUIT-003 Ce1;ce1P;ce3U;ce4Glc;ce5M;ce6Rot;ce7S;1Dig;1c;2Ama;3AsTm;4Azd]] coupling control protocol and respirometric cell viability test (CCV protocol) without oligomycin.
::::* [[SUIT-003 Ce1;ce1P;ce3U;ce4Glc;ce5M;ce6Rot;ce7S;1Dig;1c;2Ama;3AsTm;4Azd]] coupling-control protocol and respirometric cell viability test (CCV protocol) without oligomycin.
::::* [[SUIT-003 Ce1;ce2U-]]
::::* [[SUIT-003 Ce1;ce2U-]]
::::* [[SUIT-003 Ce1;ce2SD;ce3Omy;ce4U-]] Β 
::::* [[SUIT-003 Ce1;ce2SD;ce3Omy;ce4U-]] Β 
::::* [[SUIT-003 Ce1;ce2SD;ce3U;ce4Rot;ce5Ama]]
::::* [[SUIT-003 Ce1;ce2SD;ce3U;ce4Rot;ce5Ama]]
::::* [[SUIT-003 Ce1;ce2U;ce3Rot;ce4S;ce5Ama]]
::::* [[SUIT-003 Ce1;ce2U;ce3Rot;ce4S;ce5Ama]]
::::* [[SUIT-006]]: Coupling control protocol for mt-preparations (mtprep), counterpart to SUIT-003 for non-permeabilized cells (ce).
::::* [[SUIT-006]]: Coupling-control protocol for mt-preparations (mtprep), counterpart to SUIT-003 for non-permeabilized cells (ce).





Latest revision as of 12:36, 25 November 2020


high-resolution terminology - matching measurements at high-resolution


SUIT-003 O2 ce D061

Description

Ce1;(ce2Omy);ce3U;ce4Rot;ce5DMSO;ce6DMSO;ce7Ama.png

Abbreviation: CCP-ce Snv,Mnanv - control

Reference: B Carrier control for the coupling-control protocol for living cells with cell permeable compounds MitoKit-CII/Succinate-nv and MitoKit-CII/Malonate-nv - SUIT-003 O2 ce D060

SUIT number: D061_ce1;(ce2Omy);ce3U;ce4Rot;ce5DMSO;ce6DMSO;ce7Ama

O2k-Application: O2

MitoPedia: SUIT - Coupling-control protocol (CCP) with the carrier of the plasma membrane-permeable succinate (MitoKit-CII/Succinate-nv) and plasma membrane-permeable malonate (MitoKit-CII/Malonate-nv) in living cells (ce): DMSO.
SUIT protocol pattern: ce1;(ce2Omy);ce3U;ce4DMSO;ce5DMSO;ce6Rot;ce7Ama

SUIT-003 O2 ce D061 protocol is a control for the SUIT-003 O2 ce D060, with the addition of the carrier DMSO instead of the plasma membrane-permeable succinate (MitoKit-CII/Succinate-nv) and plasma membrane-permeable malonate (MitoKit-CII/Malonate-nv). Moreover, the SUIT-003 O2 ce D061 protocol allows evaluating the coupling control of living cells. Respiratory capacities are tested in a sequence of coupling states: ROUTINE and Electron transfer pathway. Optionally, to study LEAK respiration, the phosphorylation system might be inhibited by oligomycin. The final concentration of oligomycin has to be carefully optimized for various cell types, to minimize the inhibitory effect on the electron transfer system which would lead to an underestimation of ET capacity. SUIT-003 O2 ce D061 protocol is a control for the SUIT-003 O2 ce D060, with the addition of the carrier DMSO instead of the plasma membrane-permeable succinate ([[[MitoKit-CII/Succinate-nv]]) and plasma membrane-permeable malonate (MitoKit-CII/Malonate-nv). Moreover, the SUIT-003 O2 ce D061 protocol allows evaluating the coupling control of living cells. Respiratory capacities are tested in a sequence of coupling states: ROUTINE and Electron transfer pathway. Optionally, to study LEAK respiration, the phosphorylation system might be inhibited by oligomycin. The final concentration of oligomycin has to be carefully optimized for various cell types, to minimize the inhibitory effect on the electron transfer system which would lead to an underestimation of ET capacity.


Communicated by  Garcia-Souza LF, Cardoso LHD and Gnaiger E(last update 2019-07-02)
MitoPedia: SUIT

Steps and respiratory states

Ce1;(ce2Omy);ce3U;ce4Rot;ce5DMSO;ce6DMSO;ce7Ama.png

Step State Pathway Q-junction Comment - Events (E) and Marks (M)
ce1 ROUTINE ce1
  • ROUTINE respiration in the physiological coupling state R. Externally added permeable substrates could contribute to this respiratory state.


(ce2Omy) L(Omy) ce1;(ce2Omy)
  • Non-phosphorylating resting state (LEAK state); LEAK-respiration, L(Omy), after blocking the ATP synthase with oligomycin.
  • The addition of oligomycin is optional depending on the experimental question to resolve.
ce3U E cce1;(ce2Omy);ce3U
ce4Rot ROX ce1;(ce2Omy);ce3U;ce4Rot
  • Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated either after inhibition of CIII (e.g. antimycin A, myxothiazol), CIV (e.g. Cyanide) or in the absence of endogenous fuel-substrates. Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration.
ce5DMSO ROX ce1;(ce2Omy);ce3U;ce4Rot;ce5DMSO
  • Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated either after inhibition of CIII (e.g. antimycin A, myxothiazol), CIV (e.g. Cyanide) or in the absence of endogenous fuel-substrates. Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration.
ce6DMSO ROX ce1;(ce2Omy);ce3U;ce4Rot;ce5DMSO;ce6DMSO
  • Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated either after inhibition of CIII (e.g. antimycin A, myxothiazol), CIV (e.g. Cyanide) or in the absence of endogenous fuel-substrates. Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration.
ce7Ama ROX ce1;(ce2Omy);ce3U;ce4Rot;ce5DMSO;ce6DMSO;ce7Ama
  • Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated either after inhibition of CIII (e.g. antimycin A, myxothiazol), CIV (e.g. Cyanide) or in the absence of endogenous fuel-substrates. Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration.

Strengths and limitations

+ This protocol is a control for SUIT-003 O2 ce D060, with titrations of the carrier DMSO.
+ Reasonable duration of the experiment.
- To obtain LEAK respiration, the concentration of oligomycin has to be carefully tested to avoid inhibitory effects in the evaluation of the ET capacity.
- Careful washing is required after the experiment to avoid carry-over of inhibitors and uncoupler.


Compare SUIT protocols


References

MitoPedia concepts: SUIT protocol, SUIT B, Find 


MitoPedia methods: Respirometry